Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Kura Oncology (KURA) Income from Continuing Operations: 2024-2025

Historic Income from Continuing Operations for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to -$74.1 million.

  • Kura Oncology's Income from Continuing Operations fell 36.23% to -$74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$214.9 million, marking a year-over-year change of. This contributed to the annual value of -$174.0 million for FY2024, which is 13.99% down from last year.
  • Per Kura Oncology's latest filing, its Income from Continuing Operations stood at -$74.1 million for Q3 2025, which was down 12.09% from -$66.1 million recorded in Q2 2025.
  • Kura Oncology's 5-year Income from Continuing Operations high stood at -$17.2 million for Q4 2024, and its period low was -$74.1 million during Q3 2025.